LAVAL, QC / ACCESSWIRE / May 10, 2023 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) is proud to recognize May as Mental Health Awareness Month by continuing efforts that highlight the importance of educating and supporting those with mental health care needs.
With more people finding value in speaking with a mental health professional and seeking treatment, this heightened focus on mental health has never been more important.1 By the end of 2022, 37% of Americans rated their mental health as "fair or poor"-a 6% increase from 2021. Twenty-six percent expect to experience more stress throughout 2023.2 Dedicating the month of May to mental health offers those with concerns the reminder and opportunity to prioritize self-awareness and self-care.
This year, Bausch Health is also proud to highlight 20 years of trusted legacy with WELLBUTRIN XL.3,4 Since its FDA approval in 2003, WELLBUTRIN XL has been prescribed by more than 440,000 healthcare professionals to more than 7 million patients for a total of more than 51 million prescriptions filled.5-7
WELLBUTRIN XL offers a proven clinical profile, convenient dosing for patients, and comprehensive support for eligible patients.3 Visit wellbutrinXL.com to access information regarding mental health and depression.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our healthcare products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
INDICATION
WELLBUTRIN XL® (bupropion hydrochloride extended-release tablets) is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder, and for the prevention of autumn-winter seasonal depression (seasonal affective disorder).
IMPORTANT SAFETY INFORMATION
WARNING: CHANGES IN THINKING AND BEHAVIOR, DEPRESSION, AND SUICIDAL THOUGHTS OR ACTIONS Suicidal Thoughts or Actions and Antidepressant Drugs Antidepressants may increase the risk of suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. Depression or other serious mental illnesses are the most important causes of suicidal thoughts and actions. People who have (or have a family history of) bipolar illness or suicidal thoughts or actions may have a particularly high risk. Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if symptoms such as anxiety, irritability, impulsivity, trouble sleeping, aggressive behavior or suicidal thoughts are new, worse or worry you. WELLBUTRIN XL has not been evaluated for use in patients under the age of 18. |
Call your healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:
Although WELLBUTRIN XL is not a treatment for quitting smoking, it contains the same active ingredient (bupropion) as ZYBAN, which is used to help patients quit smoking.
Some people have had serious side effects while taking bupropion to help them quit smoking, including:
New or worse mental health problems, such as changes in behavior or thinking, aggression, hostility, agitation, depression, or suicidal thoughts or actions. Some people had these symptoms when they began taking bupropion, and others developed them after several weeks of treatment, or after stopping bupropion. These symptoms happened more often in people who had a history of mental health problems before taking bupropion than in people without a history of mental health problems.
Stop taking WELLBUTRIN XL and call your healthcare provider right away if you, your family, or caregiver notice any of these symptoms. Work with your healthcare provider to decide whether you should continue to take WELLBUTRIN XL. In many people, these symptoms went away after stopping WELLBUTRIN XL, but in some people, symptoms continued after stopping WELLBUTRIN XL. It is important for you to follow-up with your healthcare provider until your symptoms go away.
Before taking WELLBUTRIN XL, tell your healthcare provider if you have ever had depression or other mental health problems. You should also tell your healthcare provider about any symptoms you had during other times you tried to quit smoking, with or without bupropion.
What Other Important Information Should I Know About WELLBUTRIN XL?
Do not take WELLBUTRIN XL if you:
Although WELLBUTRIN XL is not a treatment for quitting smoking, it contains the same active ingredient (bupropion) as ZYBAN, which is used to help patients quit smoking. Before taking WELLBUTRIN XL, tell your healthcare provider if you have ever had depression, suicidal thoughts or actions, or other mental health problems or any symptoms you had during other times you tried to quit smoking with or without bupropion. Also, tell your healthcare provider about your other medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Many medicines increase your chances of having seizures or cause other serious side effects if you take them while you are using WELLBUTRIN XL.
The most common side effects of WELLBUTRIN XL include: trouble sleeping, stuffy nose, dry mouth, dizziness, feeling anxious, nausea, constipation, and joint aches.
Click here to read the Medication Guide carefully before you start using WELLBUTRIN XL. If you have any questions about WELLBUTRIN XL, ask your healthcare provider or pharmacist.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatchor call 1-800-FDA-1088. You may also contact Bausch Health Customer Service at 1-800-321-4576.
References
1. American Psychological Association. Demand for mental health treatment continues to increase, say psychologists. https://www.apa.org/news/press/releases/2021/10/mental-health-treatment-demand. Accessed March 29, 2023.
2. American Psychiatric Association. Americans anticipate higher stress at the start of 2023 and grade their mental health worse. https://www.psychiatry.org/news-room/news-releases/americans-anticipate-higher-stress-at-the-start-of. Accessed March 29, 2023.
3. WELLBUTRIN XL (bupropion hydrochloride extended-release) Prescribing Information. Bausch Health Companies Inc.
4. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21515ltr.pdf. Accessed March 29, 2023.
5. Data on File. IQVIA: Unique prescribers. 2022.
6. Data on File. IQVIA: Total patients. 2022.
7. Data on File. IQVIA: Total prescriptions. 2022.
Investor Contact: | Media Contact: |
Mark Maico | Kevin Wiggins |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
(908) 541-2102 | (908) 541-3785 |
(877) 281-6642 (toll free) |
WELLBUTRIN XL is a registered trademark of GlaxoSmithKline LLC used under license.
Any other product/brand names and/or logos are trademarks of the respective owners.
© 2023 Bausch Health Companies Inc. or its affiliates. WXL.0024.USA.23V2.0
Last Trade: | US$6.21 |
Daily Change: | 0.02 0.32 |
Daily Volume: | 1,425,006 |
Market Cap: | US$2.280B |
August 01, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB